GSA Capital Partners LLP Acquires 83,505 Shares of Fulcrum Therapeutics, Inc. $FULC

GSA Capital Partners LLP grew its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 256.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 116,068 shares of the company’s stock after buying an additional 83,505 shares during the period. GSA Capital Partners LLP’s holdings in Fulcrum Therapeutics were worth $1,068,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at $164,000. Jane Street Group LLC boosted its position in shares of Fulcrum Therapeutics by 62.1% during the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after purchasing an additional 45,157 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after buying an additional 2,677 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at about $93,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Fulcrum Therapeutics by 57.3% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock valued at $2,357,000 after buying an additional 124,798 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Insider Activity at Fulcrum Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. The trade was a 40.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the transaction, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is owned by company insiders.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock opened at $11.73 on Friday. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $15.74. The firm’s 50-day simple moving average is $10.95 and its 200 day simple moving average is $9.37. The stock has a market cap of $634.83 million, a PE ratio of -9.94 and a beta of 3.19.

Analyst Ratings Changes

FULC has been the topic of several recent research reports. Bank of America increased their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. HC Wainwright upped their target price on Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.11.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.